Sylvie Ryckebusch
Corporate Officer/Principal bij BIOINVENT INTERNATIONAL AB
Vermogen: 42 331 $ op 30-04-2024
Actieve functies van Sylvie Ryckebusch
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIOINVENT INTERNATIONAL AB | Corporate Officer/Principal | 09-06-2022 | - |
Domain Therapeutics SA
 Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Directeur/Bestuurslid | - | - |
Loopbaan van Sylvie Ryckebusch
Opleiding van Sylvie Ryckebusch
| California Institute of Technology | Doctorate Degree |
| University of Maryland | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Frankrijk | 2 |
| Zweden | 2 |
Operationeel
| Director/Board Member | 1 |
| Doctorate Degree | 1 |
| Corporate Officer/Principal | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| BIOINVENT INTERNATIONAL AB | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Domain Therapeutics SA
Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
- Beurs
- Insiders
- Sylvie Ryckebusch
- Ervaring
